{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:37:04Z","timestamp":1792132624581,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["WI177419 EU"],"award-info":[{"award-number":["WI177419 EU"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s15010-024-02448-x","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:23:48Z","timestamp":1733498628000},"page":"1155-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-9497","authenticated-orcid":false,"given":"Omar","family":"Elkayal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-9484","authenticated-orcid":false,"given":"Yannick","family":"Hoffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-3045","authenticated-orcid":false,"given":"Beatrijs","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2103","authenticated-orcid":false,"given":"Ruth","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-1350","authenticated-orcid":false,"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3897","authenticated-orcid":false,"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2448_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1086\/380637","volume":"38","author":"O Marchetti","year":"2004","unstructured":"Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of Candidemia in Swiss Tertiary Care hospitals: secular trends, 1991\u20132000. Clin Infect Dis. 2004;38:311\u201320.","journal-title":"Clin Infect Dis"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12539","volume":"20","author":"J Guinea","year":"2014","unstructured":"Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:5\u201310.","journal-title":"Clin Microbiol Infect"},{"key":"2448_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","volume":"40","author":"O Lortholary","year":"2014","unstructured":"Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010). Intensive Care Med. 2014;40:1303\u201312.","journal-title":"Intensive Care Med"},{"key":"2448_CR4","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","volume":"379","author":"SS Magill","year":"2018","unstructured":"Magill SS, O\u2019Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of Health Care\u2013Associated infections in U.S. hospitals. N Engl J Med. 2018;379:1732\u201344.","journal-title":"N Engl J Med"},{"key":"2448_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice Guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis off Publ Infect Dis Soc Am. 2016;62:e1\u201350.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"key":"2448_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19\u201337.","journal-title":"Clin Microbiol Infect"},{"key":"2448_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/1568005014606107","volume":"1","author":"J Liu","year":"2001","unstructured":"Liu J, Balasubramanian MK. 1,3-beta-glucan synthase: a useful target for antifungal drugs. Curr Drug Targets - Infect Disord. 2001;1:159\u201369.","journal-title":"Curr Drug Targets - Infect Disord"},{"key":"2448_CR8","doi-asserted-by":"crossref","unstructured":"Denning DW. Echinocandin antifungal drugs. LANCET. 2003;362.","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"2448_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/0091270004265644","volume":"44","author":"JA Dowell","year":"2004","unstructured":"Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal. J Clin Pharmacol. 2004;44:590\u20138.","journal-title":"J Clin Pharmacol"},{"key":"2448_CR10","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","volume":"54","author":"D Andes","year":"2010","unstructured":"Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. Vivo comparison of the pharmacodynamic targets for Echinocandin drugs against Candida Species. Antimicrob Agents Chemother. 2010;54:2497\u2013506.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1128\/AAC.01061-07","volume":"52","author":"D Andes","year":"2008","unstructured":"Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of Anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:539\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1128\/AAC.01279-08","volume":"53","author":"BD Damle","year":"2009","unstructured":"Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In Vitro and in vivo studies to characterize the Clearance mechanism and potential cytochrome P450 interactions of Anidulafungin. Antimicrob Agents Chemother. 2009;53:1149\u201356.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position Paper#. Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"2448_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/jcpt.13211","volume":"45","author":"X Liu","year":"2020","unstructured":"Liu X, Liu D, Pan Y, Li Y. Pharmacokinetic\/pharmacodynamics variability of echinocandins in critically ill patients: a systematic review and meta-analysis. J Clin Pharm Ther. 2020;45:1207\u201317.","journal-title":"J Clin Pharm Ther"},{"key":"2448_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ajhp\/zxad021","volume":"80","author":"YS Alsowaida","year":"2023","unstructured":"Alsowaida YS, Alamer A, Thabit AK, Almulhim AS, Aleissa MM, Kalbasi A, et al. Echinocandin exposures in obese patients: a scoping review and clinical perspectives. Am J Health Syst Pharm. 2023;80:503\u201317.","journal-title":"Am J Health Syst Pharm"},{"key":"2448_CR16","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI A New Equation to Estimate Glomerular Filtration Rate, et al. editors. Ann Intern Med. 2009;150:604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2448_CR17","unstructured":"Anidulafungin. EUCAST rationale document."},{"key":"2448_CR18","unstructured":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. [cited 2023 Jul 21]; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf"},{"key":"2448_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25\u201336.","journal-title":"Korean J Anesthesiol"},{"key":"2448_CR20","unstructured":"Wickham H. The tidyverse [Internet]. Presentation. 2016. Available from: http:\/\/tidyverse.org"},{"key":"2448_CR21","unstructured":"Grolemund HW. and G. Welcome| R for Data Science [Internet]. [cited 2023 Jan 11]. https:\/\/r4ds.had.co.nz\/"},{"key":"2448_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"key":"2448_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013;2:50.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2448_CR24","unstructured":"Baron KT. mrgsolve: Simulate from ODE-Based Models."},{"key":"2448_CR25","first-page":"1429","volume":"72","author":"H Dupont","year":"2017","unstructured":"Dupont H, Massias L, Jung B, Ammenouche N, Montravers P. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis. J Antimicrob Chemother. 2017;72:1429\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"2448_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cpt.1831","volume":"108","author":"R Xie","year":"2020","unstructured":"Xie R, McFadyen L, Raber S, Swanson R, Tawadrous M, Leister-Tebbe H, et al. Population Analysis of Anidulafungin in infants to older adults with confirmed or suspected invasive candidiasis. Clin Pharmacol Ther. 2020;108:316\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"2448_CR27","doi-asserted-by":"crossref","unstructured":"Hall RG, Liu S, Putnam WC, Kallem R, Gumbo T, Pai MP. Optimizing anidulafungin exposure across a wide adult body size range. Antimicrob Agents Chemother. 2023;67:e00820\u201323.","DOI":"10.1128\/aac.00820-23"},{"key":"2448_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bcp.14457","volume":"87","author":"I Kapralos","year":"2021","unstructured":"Kapralos I, Mainas E, Apostolopoulou O, Siopi M, Neroutsos E, Apostolidi S, et al. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. Br J Clin Pharmacol. 2021;87:1024\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"2448_CR29","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1128\/AAC.02809-13","volume":"58","author":"P Liu","year":"2014","unstructured":"Liu P, Mould DR. Population Pharmacokinetic-Pharmacodynamic analysis of Voriconazole and Anidulafungin in Adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58:4727\u201336.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR30","doi-asserted-by":"publisher","first-page":"e00063","DOI":"10.1128\/AAC.00063-18","volume":"62","author":"RE Wasmann","year":"2018","unstructured":"Wasmann RE, ter Heine R, van Dongen EP, Burger DM, Lempers VJ, Knibbe CA, et al. Pharmacokinetics of Anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother. 2018;62:e00063\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jac\/dku477","volume":"70","author":"RJM Br\u00fcggemann","year":"2015","unstructured":"Br\u00fcggemann RJM, Van Der Velden WJFM, Knibbe CAJ, Colbers A, Hol S, Burger DM, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother. 2015;70:1166\u201374.","journal-title":"J Antimicrob Chemother"},{"key":"2448_CR32","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1128\/AAC.02139-12","volume":"57","author":"P Liu","year":"2013","unstructured":"Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of Anidulafungin in critically ill patients with Candidemia\/Invasive candidiasis. Antimicrob Agents Chemother. 2013;57:1672\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR33","first-page":"361","volume":"46","author":"MLNG Malbrain","year":"2014","unstructured":"Malbrain MLNG, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anestezjol Intensywna Ter. 2014;46:361\u201380.","journal-title":"Anestezjol Intensywna Ter"},{"key":"2448_CR34","doi-asserted-by":"crossref","unstructured":"National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in Acute Lung Injury. N Engl J Med. 2006;354(24):2564\u201375.","DOI":"10.1056\/NEJMoa062200"},{"key":"2448_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","volume":"18","author":"M Ruhnke","year":"2012","unstructured":"Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;18:680\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"2448_CR36","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1093\/jac\/dkx116","volume":"72","author":"BJ Kullberg","year":"2017","unstructured":"Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva J-A, Garbino J, et al. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017;72:2368\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"2448_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijantimicag.2012.07.018","volume":"40","author":"G Dimopoulos","year":"2012","unstructured":"Dimopoulos G, Paiva J-A, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis. Int J Antimicrob Agents. 2012;40:521\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"2448_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","volume":"44","author":"HY Kim","year":"2022","unstructured":"Kim HY, Baldelli S, M\u00e4rtson A-G, Stocker S, Alffenaar J-W, Cattaneo D, et al. Therapeutic drug monitoring of the Echinocandin Antifungal agents: is there a role in clinical practice? A position Statement of the Anti-infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022;44:198\u2013214.","journal-title":"Ther Drug Monit"},{"key":"2448_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijantimicag.2014.07.019","volume":"44","author":"TN Doan","year":"2014","unstructured":"Doan TN, Kong DCM, Patel K, Walker P, Spencer A, Kirkpatrick CMJ. Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia. Int J Antimicrob Agents. 2014;44:450\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"2448_CR40","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1128\/AAC.00378-19","volume":"63","author":"S Luque","year":"2019","unstructured":"Luque S, Hope W, Campillo N, Mu\u00f1oz-Berm\u00fadez R, Sorli L, Barcel\u00f3-Vidal J, et al. Population Pharmacokinetics of Anidulafungin in critically ill patients. Antimicrob Agents Chemother. 2019;63:e00378\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"2448_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","volume":"33","author":"NM Mehta","year":"2007","unstructured":"Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33:1018\u201324.","journal-title":"Intensive Care Med"},{"key":"2448_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","volume":"52","author":"JA Roberts","year":"2013","unstructured":"Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1\u20138.","journal-title":"Clin Pharmacokinet"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02448-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:54:41Z","timestamp":1749016481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02448-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02448-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (NCT04045366) was conducted following the ethical committee approval number S54510, under the study protocol registered with the Ethics Committee Research UZ\/KU Leuven. All procedures conducted within this study were executed in strict adherence to the principles of the Declaration of Helsinki, as well as the principles of good clinical practice, and in accordance with all pertinent regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"OE, YH, BM, and RVD have nothing to disclose. KL received consultancy fees Mundipharma, speaker fees from Pfizer, Gilead, Mundipharma and FUJIFILM Wako chemicals Europe GmbH, a service fee from TECOmedical; a fee for Advisory Board participation from Pfizer and travel support from Pfizer, Gilead and AstraZeneca; outside the submitted work. JW reports investigator-initiated grants from Pfizer, Gilead, and MSD; consulting fees from Pfizer and Gilead; speakers\u2019 fees from Pfizer, Gilead, and MSD; travel fees from Pfizer, Gilead, and MSD; participation in advisory boards of Pfizer and Gilead; receipt of study drugs from MSD; outside the submitted work. IS is supported by the Clinical Research Fund of UZ Leuven and reports consulting fees from Pfizer and Cidara; speakers\u2019 fees from Pfizer; travel support from Pfizer; outside the submitted work. ED received consultancy fees from Alimentiv and argenx, lecture fees from Celltrion and Galapagos, and financial support from Janssen, Pfizer, Prometheus, R-Biopharm, and Sandoz, outside the submitted work, with all honoraria\/fees being paid to KU Leuven and not to any personal account of ED.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}